Remdesivir Intermediate CAS 1354823-36-1 COVID-19 N-[(S)-(4-nitrophenoxy)phenoxyphosphinyl]-L-Alanine 2-ethylbutyl ester

Description:

N-[(S)-(4-nitrophenoxy)phenoxyphosphinyl]-L-Alanine 2-ethylbutyl ester

CAS: 1354823-36-1

Intermedia Remdesiviri (CAS 1809249-37-3) ad curationem COVID-19

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Descriptio:

Chemical Properties:

Nomen chemicum N-[(S)-(4-nitrophenoxy)phenoxyphosphinyl]-L-Alanine 2-ethylbutyl ester
Synonyma Remdesivir Medius;Remdesivir Side Chain;Remdesivir p-NitroPhenoxy L-Alanine Impurity;Remdesivir immunditia 4;Remdesivir-002;(S) -2-Ethylbutyl 2-(((S)-(4-nitrophenoxy)(phenoxy)-phosphoryl)-amino)propanoatum
CAS Number 1354823-36-1
CATTUS Number RF-PI297
Stock Status In Stock, Productio Ascendite usque ad Centum chiliogrammata
Formulae hypotheticae C21H27N2O7P
M. Pondus 450.42
Brand Ruifu Chemical

Specifications:

Item Specifications
Aspectus Alba ad fere album pulveris
Lepidium sativum IR, HPLC
Damnum in Siccatio ≤1.0%
una immunditia ≤0.50%
Metalla gravis ≤20ppm
Puritas ≥98.0%
Test Standard Enterprise Standard
Consuetudinem Medium Remdesiviri (CAS 1809249-37-3);COVID 19

Sarcina & Repono:

sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.

commoda:

1

FAQ:

Applicatio:

N-[(S)-(4-nitrophenoxy)phenoxyphosphinyl]-L-Alanine 2-ethylbutyl ester (CAS 1809249-37-3, GS-5734), quod medicamentum novum antivirale investigationis originaliter est ad curationem morbi virus virus et Marburg infectio virium Marburg, et postea etiam inventa est ut ostenderet actionem antiviralem contra coronaviroses (eg SARS-Cov-2/. Covid 19).In ingruente novo Coronaviro Morbus 2019 (COVID-19), Remdesivir (CAS 1809249-37-3) est unus e productis investigationis CoVID-19 affinis.Remdesivir, sub noto nomine Veklury venditus, est medicamentum latum-spectrum antivirale a comitatu Gilead Scientiarum biopharmaceutico elaboratum.Datur per iniectionem in venam.Durante COVID-19 pandemico, Remdesivir probatus est vel auctoritate usus ad subitum tractandum COVID-19 in regionibus circiter 50.Renovatae normae a Mundi Salus Organizatio mense Novembri 2020 includunt commendationem conditionalem contra usum Remdesiviri ad tractandum de COVID-19.

Epistulam tuam hic scribe et mitte nobis